{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:27:10Z","timestamp":1774531630974,"version":"3.50.1"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T00:00:00Z","timestamp":1399334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0094709","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T20:34:33Z","timestamp":1399408473000},"page":"e94709","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Who Has Used Internal Company Documents for Biomedical and Public Health Research and Where Did They Find Them?"],"prefix":"10.1371","volume":"9","author":[{"given":"L. Susan","family":"Wieland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lainie","family":"Rutkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Swaroop","family":"Vedula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher N.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori M.","family":"Rosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Twose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirosha","family":"Mahendraratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Dickersin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,5,6]]},"reference":[{"key":"ref1","volume":"14","unstructured":"Song F, Parekh S, Hooper L, Loke YK, Ryder J, <etal>et al<\/etal>.. (2010) Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess <volume>14<\/volume> : iii, ix-xi, 1\u2013193."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e1001189","DOI":"10.1371\/journal.pmed.1001189","article-title":"Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database","volume":"9","author":"EH Turner","year":"2012","journal-title":"PLoS Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1258\/jrsm.2011.11k042","article-title":"Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO","volume":"104","author":"K Dickersin","year":"2011","journal-title":"J R Soc Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use","volume":"361","author":"SS Vedula","year":"2009","journal-title":"N Engl J Med"},{"key":"ref5","first-page":"15","article-title":"How important is publication bias? A synthesis of available data","volume":"9","author":"K Dickersin","year":"1997","journal-title":"AIDS Educ Prev"},{"key":"ref6","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"12","author":"A Lundh","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","article-title":"Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards","volume":"267","author":"K Dickersin","year":"1992","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.291.20.2457","article-title":"Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles","volume":"291","author":"AW Chan","year":"2004","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.38488.385995.8F","article-title":"Fate of biomedical research protocols and publication bias in France: retrospective cohort study","volume":"331","author":"E Decullier","year":"2005","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1749-6632.1993.tb26343.x","article-title":"Publication bias: the problem that won&apos;t go away","volume":"703","author":"K Dickersin","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1503\/cmaj.1041086","article-title":"Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research","volume":"171","author":"AW Chan","year":"2004","journal-title":"CMAJ"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1986.4.10.1529","article-title":"Publication bias: the case for an international registry of clinical trials","volume":"4","author":"RJ Simes","year":"1986","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, <etal>et al<\/etal>.. (2011) Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Database Syst Rev: MR000031.","DOI":"10.1111\/j.1756-5391.2011.01149.x"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1371\/journal.pmed.0050217","article-title":"Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation","volume":"5","author":"K Rising","year":"2008","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e1001201","DOI":"10.1371\/journal.pmed.1001201","article-title":"The imperative to share clinical study reports: recommendations from the Tamiflu experience","volume":"9","author":"P Doshi","year":"2012","journal-title":"PLoS Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7326\/0003-4819-158-12-201306180-00009","article-title":"A historic moment for open science: the Yale University Open Data Access Project and Medtronic","volume":"158","author":"HM Krumholz","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e1001378","DOI":"10.1371\/journal.pmed.1001378","article-title":"Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin","volume":"10","author":"SS Vedula","year":"2013","journal-title":"PLoS Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1745-6215-13-136","article-title":"Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation","volume":"13","author":"SS Vedula","year":"2012","journal-title":"Trials"},{"key":"ref19","first-page":"CD008965","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"1","author":"T Jefferson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0025-6196(11)60563-6","article-title":"Open doorway to truth: legacy of the Minnesota tobacco trial","volume":"84","author":"RD Hurt","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"f2865","DOI":"10.1136\/bmj.f2865","article-title":"Restoring invisible and abandoned trials: a call for people to publish the findings","volume":"346","author":"P Doshi","year":"2013","journal-title":"BMJ"},{"key":"ref22","volume":"3","unstructured":"Doshi P, Jefferson T (2013) Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open <volume>3<\/volume>.."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-149-4-200808190-00006","article-title":"The ADVANTAGE seeding trial: a review of internal documents","volume":"149","author":"KP Hill","year":"2008","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1057\/jphp.2011.60","article-title":"The manufacture of lifestyle: the role of corporations in unhealthy living","volume":"33","author":"N Freudenberg","year":"2012","journal-title":"J Public Health Policy"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2105\/AJPH.2008.138115","article-title":"The role of corporate credibility in legitimizing disease promotion","volume":"99","author":"PA McDaniel","year":"2009","journal-title":"Am J Public Health"},{"key":"ref26","unstructured":"The UCSF Tobacco Documents Bibliography. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.library.ucsf.edu\/tobacco\/docsbiblio\" xlink:type=\"simple\">www.library.ucsf.edu\/tobacco\/docsbiblio<\/ext-link> (Accessed 17 January 2013): UCSF Library and Center for Knowledge Management."},{"key":"ref27","unstructured":"Drug Industry Document Archive. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dida.library.ucsf.edu\/\" xlink:type=\"simple\">http:\/\/dida.library.ucsf.edu\/<\/ext-link> (Accessed 11 February 2013): UCSF Library and Center for Knowledge Management."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"d7898","DOI":"10.1136\/bmj.d7898","article-title":"Rethinking credible evidence synthesis","volume":"344","author":"P Doshi","year":"2012","journal-title":"BMJ"},{"key":"ref29","unstructured":"The Cochrane Collaboration (2013) Cochrane Collaboration announces formal support for AllTrials initiative. News release 19 April 2013. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cochrane.org\/node\/4906\" xlink:type=\"simple\">http:\/\/www.cochrane.org\/node\/4906<\/ext-link> (Accessed 7 July 2013)."},{"key":"ref30","unstructured":"Food and Drug Administration (2013) Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for Comments. Federal Register. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.federalregister.gov\/articles\/2013\/06\/04\/2013-13083\/availability-of-masked-and-de-identified-non-summary-safety-and-efficacy-data-request-for-comments\" xlink:type=\"simple\">https:\/\/www.federalregister.gov\/articles\/2013\/06\/04\/2013-13083\/availability-of-masked-and-de-identified-non-summary-safety-and-efficacy-data-request-for-comments<\/ext-link> (Accessed 7 July 2013)."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"ii8","DOI":"10.1136\/tc.2010.041921","article-title":"Tobacco documents research methodology","volume":"20","author":"SJ Anderson","year":"2011","journal-title":"Tob Control"},{"key":"ref32","unstructured":"WHO (2004) The tobacco industry documents. What they are, what they tell us, and how to search them. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/tobacco\/communications\/TI_manual_content.pdf\" xlink:type=\"simple\">http:\/\/www.who.int\/tobacco\/communications\/TI_manual_content.pdf<\/ext-link> (Accessed 12 February, 2013)."},{"key":"ref33","unstructured":"Publication and access to clinical-trial data: an inclusive development process. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000556.jsp\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000556.jsp<\/ext-link>. (Accessed December 15, 2013)."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"d8013","DOI":"10.1136\/bmj.d8013","article-title":"Out of sight but not out of mind: how to search for unpublished clinical trial evidence","volume":"344","author":"AW Chan","year":"2012","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","article-title":"Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis","volume":"292","author":"BM Psaty","year":"2004","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","article-title":"Narrative review: the promotion of gabapentin: an analysis of internal industry documents","volume":"145","author":"MA Steinman","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JRS-2008-0426","article-title":"Clinical trials and drug promotion: Selective reporting of study 329","volume":"20","author":"JN Jureidini","year":"2008","journal-title":"International Journal of Risk and Safety in Medicine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/08989620802194384","article-title":"Industry-sponsored ghostwriting in clinical trial reporting: a case study","volume":"15","author":"LB McHenry","year":"2008","journal-title":"Account Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/jama.299.15.1813","article-title":"Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation","volume":"299","author":"BM Psaty","year":"2008","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1001\/jama.299.15.1800","article-title":"Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation","volume":"299","author":"JS Ross","year":"2008","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/08989620802689847","article-title":"Moral disengagement in the corporate world","volume":"16","author":"J White","year":"2009","journal-title":"Account Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1542\/peds.84.2.374","article-title":"Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians","volume":"84","author":"J Hetherington","year":"1989","journal-title":"Pediatrics"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11013-009-9129-3","article-title":"Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster","volume":"33","author":"K Applbaum","year":"2009","journal-title":"Cult Med Psychiatry"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.socscimed.2009.05.001","article-title":"The promotion of olanzapine in primary care: an examination of internal industry documents","volume":"69","author":"GI Spielmans","year":"2009","journal-title":"Soc Sci Med"},{"key":"ref45","first-page":"30","article-title":"Adverse drug effects not detected at licensing review: Regulatory autopsy of olanzapine","volume":"37","author":"S Woods","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1891\/ehpp.8.1.77","article-title":"Court filing makes public my previously suppressed analysis of Paxil&apos;s effects","volume":"8","author":"PR Breggin","year":"2006","journal-title":"Ethical Hum Psychol Psychiatry"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/08989621.2011.542683","article-title":"Conflicted medical journals and the failure of trust","volume":"18","author":"JN Jureidini","year":"2011","journal-title":"Account Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bmj.39024.487720.68","article-title":"What have we learnt from Vioxx?","volume":"334","author":"HM Krumholz","year":"2007","journal-title":"BMJ"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/archinternmed.2010.461","article-title":"Persistence of cardiovascular risk after rofecoxib discontinuation","volume":"170","author":"JS Ross","year":"2010","journal-title":"Arch Intern Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1371\/journal.pmed.0040134","article-title":"Characteristics and impact of drug detailing for gabapentin","volume":"4","author":"MA Steinman","year":"2007","journal-title":"PLoS Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp0808659","article-title":"The Neurontin legacy\u2014marketing through misinformation and manipulation","volume":"360","author":"CS Landefeld","year":"2009","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e1000335","DOI":"10.1371\/journal.pmed.1000335","article-title":"The haunting of medical journals: how ghostwriting sold \u201cHRT\u201d","volume":"7","author":"AJ Fugh-Berman","year":"2010","journal-title":"PLoS Med"},{"key":"ref53","first-page":"966","article-title":"The origin of MDMA (\u201cecstasy\u201d)\u2014separating the facts from the myth","volume":"61","author":"S Bernschneider-Reif","year":"2006","journal-title":"Pharmazie"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1353\/bhm.2005.0153","article-title":"Releasing the flood waters: diuril and the reshaping of hypertension","volume":"79","author":"JA Greene","year":"2005","journal-title":"Bull Hist Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0094709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:22:07Z","timestamp":1648963327000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0094709"}},"subtitle":[],"editor":[{"given":"Andrey","family":"Rzhetsky","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,6]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0094709","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,6]]}}}